Skip to main content
Published Online:https://doi.org/10.3928/00904481-20150910-09

Abstract

The International Federation of Gynecology and Obstetrics and the American Congress of Obstetricians and Gynecologists support the use of new terminology for abnormal uterine bleeding (AUB) to consistently categorize AUB by etiology. The term AUB can be further classified as AUB/heavy menstrual bleeding (HMB) (replacing the term “menorrhagia”) or AUB/intermenstrual bleeding (replacing the term “metrorrhagia”). Although many cases of AUB in adolescent women are attributable to immaturity of the hypothalamic-pituitary-ovarian axis, underlying bleeding disorders should be considered in women with AUB/HMB. This article reviews the new terminology for AUB, discusses important relevant features of history and examination, presents the laboratory evaluation of HMB, and describes hormonal (oral contraceptive pills, progestin-only methods, long-acting reversible contraceptives including intrauterine systems), hematologic (tranexamic acid and desmopresin), and surgical management options for AUB/HMB. [Pediatr Ann. 2015;44(9):e218–e222.]

  • 1.Munro MG, Critchley HO, Broder MS, Fraser ISFIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011; 113(1):3–13.10.1016/j.ijgo.2010.11.011

    CrossrefGoogle Scholar
  • 2.Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012; 120(1):197–206.10.1097/AOG.0b013e318262e320

    CrossrefGoogle Scholar
  • 3.American Academy of Pediatrics Committee on AdolescenceAmerican College of Obstetricians Gynecologists Committee on Adolescent Health Care. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006; 118(5):2245–2250.10.1542/peds.2006-2481

    CrossrefGoogle Scholar
  • 4.Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004; 190(5):1216–1223.10.1016/j.ajog.2003.11.015

    CrossrefGoogle Scholar
  • 5.Mitan LAP, Slap GB. Dysfunctional uterine bleeding. In: , Neinstein LS, Gordon CM, Katzman DK, Rosen DS, Woods ER, eds. Adolescent Health Care: A Practical Guide. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007.

    Google Scholar
  • 6.Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004; 111(7):734–740.10.1111/j.1471-0528.2004.00176.x

    CrossrefGoogle Scholar
  • 7.Vo KT, Grooms L, Klima J, Holland-Hall C, O’Brien SH. Menstrual bleeding patterns and prevalence of bleeding disorders in a multidisciplinary adolescent haematology clinic. Haemophilia. 2013; 19(1):71–75.10.1111/hae.12012

    CrossrefGoogle Scholar
  • 8.Byams VR, Kouides PA, Kulkarni R, et al.Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia. 2011; 17Suppl 1:6–13.10.1111/j.1365-2516.2011.02558.x

    CrossrefGoogle Scholar
  • 9.Sun GH, Auger KA, Aliu O, Patrick SW, DeMonner S, Davis MM. Posttonsillectomy hemorrhage in children with von Willebrand disease or hemophilia. JAMA Otolaryngol Head Neck Surg. 2013; 139(3):245–249.10.1001/jamaoto.2013.1821

    CrossrefGoogle Scholar
  • 10.Liu G, Wang Y, Zhang X, Yuan B, Han C, Xue F. Endometrial carcinoma in a 15-year-old obese patient with persistent uterine bleeding. Gynecol Endocrinol. 2014; 30(4):277–279.10.3109/09513590.2013.875156

    CrossrefGoogle Scholar
  • 11.American College of Obstetricians Gynecologists. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013; 121(4):891–896.10.1097/01.AOG.0000428646.67925.9a

    CrossrefGoogle Scholar
  • 12.Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987; 69(2):454–459.

    Google Scholar
  • 13.Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993; 123(6):893–898.10.1016/S0022-3476(05)80384-1

    CrossrefGoogle Scholar
  • 14.Sadler JE, Budde U, Eikenboom JC, et al.Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4(10):2103–2114.10.1111/j.1538-7836.2006.02146.x

    CrossrefGoogle Scholar
  • 15.Hayward CP, Harrison P, Cattaneo M, et al.Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006; 4(2):312–319.10.1111/j.1538-7836.2006.01771.x

    CrossrefGoogle Scholar
  • 16.Philipp CS, Miller CH, Faiz A, et al.Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia. 2005; 11(5):497–503.10.1111/j.1365-2516.2005.01129.x

    CrossrefGoogle Scholar
  • 17.Gresele PSubcommittee on Platelet Physiology. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015; 13(2):314–322.10.1111/jth.12792

    CrossrefGoogle Scholar
  • 18.Nichols WL, Hultin MB, James AH, et al.von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008; 14(2):171–232.10.1111/j.1365-2516.2007.01643.x

    CrossrefGoogle Scholar
  • 19.Santos M, Hendry D, Sangi-Haghpeykar H, Dietrich JE. Retrospective review of norethindrone use in adolescents. J Pediatr Adolesc Gynecol. 2014; 27(1):41–44.10.1016/j.jpag.2013.09.002

    CrossrefGoogle Scholar
  • 20.Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006; 108(4):924–929.10.1097/01.AOG.0000238343.62063.22

    CrossrefGoogle Scholar
  • 21.Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009; 80(2):113–118.10.1016/j.contraception.2009.02.008

    CrossrefGoogle Scholar
  • 22.Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception. 2010; 81(6):510–514.10.1016/j.contraception.2010.01.014

    CrossrefGoogle Scholar
  • 23.Committee on Adolescent Health Care Long-Acting Reversible Contraception Working GroupThe Amercian College of Obstetricians Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012; 120(4):983–988.10.1097/AOG.0b013e3182723b7d

    CrossrefGoogle Scholar
  • 24.Ott MA, Sucato GSCommittee on Adolescence. Contraception for adolescents. Pediatrics. 2014; 134(4):e1257–1281.10.1542/peds.2014-2300

    CrossrefGoogle Scholar
  • 25.Centers for Disease Control and Prevention (CDC). US Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 2010; 59(RR-4):1–86.

    Google Scholar
  • 26.Bayer Healthcare. Prescribing information for MIRENA (levonorgestrel-releasing intrauterine system); 2014. http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed August 7, 2015.

    Google Scholar
  • 27.Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991; 164(3):879–883.10.1016/S0002-9378(11)90533-X

    CrossrefGoogle Scholar
  • 28.Nelson AL. Levonorgestrel intrauterine system: a first-line medical treatment for heavy menstrual bleeding. Womens Health (Lond Engl). 2010; 6(3):347–356.10.2217/whe.10.16

    CrossrefGoogle Scholar
  • 29.James AH, Kouides PA, Abdul-Kadir R, et al.Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009; 201(1):12e11–18.10.1016/j.ajog.2009.04.024

    CrossrefGoogle Scholar
  • 30.Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011; 83(3):242–247.10.1016/j.contraception.2010.07.010

    CrossrefGoogle Scholar
  • 31.Committee on Adolescent Health Care; Committee on Gynecologic Practice. Committee Opinion No.580: von Willebrand disease in women. Obstet Gynecol. 2013; 122(6):1368–1373.10.1097/01.AOG.0000438961.38979.19

    CrossrefGoogle Scholar
  • 32.Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J. 1970; 4(5729):214–216.10.1136/bmj.4.5729.214

    CrossrefGoogle Scholar
  • 33.Kouides PA, Byams VR, Philipp CS, et al.Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009; 145(2):212–220.10.1111/j.1365-2141.2009.07610.x

    CrossrefGoogle Scholar
  • 34.Lukes AS, Moore KA, Muse KN, et al.Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010; 116(4):865–875.10.1097/AOG.0b013e3181f20177

    CrossrefGoogle Scholar
  • 35.Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet. 1977; 1(8017):869–872.10.1016/S0140-6736(77)91197-7

    CrossrefGoogle Scholar
  • 36.James AH, Kouides PA, Abdul-Kadir R, et al.Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011; 158(2):124–134.10.1016/j.ejogrb.2011.04.025

    CrossrefGoogle Scholar
  • 37.Hamani Y, Ben-Shachar I, Kalish Y, Porat S. Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura-induced severe uterine bleeding. Fertil Steril. 2010; 94(7):2769.e13–2769.e15.10.1016/j.fertnstert.2010.04.058

    CrossrefGoogle Scholar
  • 38.Baker WD, Soisson AP, Dodson MK. Endometrial cancer in a 14-year-old girl with Cowden syndrome: a case report. J Obstet Gynaecol Res. 2013; 39(4):876–878.10.1111/j.1447-0756.2012.02052.x

    CrossrefGoogle Scholar
  • 39.Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013; 122(1):176–185.10.1097/01.AOG.0000431815.52679.bb

    CrossrefGoogle Scholar
  • 40.Bowkley CW, Dubel GJ, Haas RA, Soares GM, Ahn SH. Uterine artery embolization for control of life-threatening hemorrhage at menarche: brief report. J Vasc Interv Radiol. 2007; 18(1 Pt 1):127–131.10.1016/j.jvir.2006.10.015

    CrossrefGoogle Scholar
  • 41.Yeasmin S, Nakayama K, Ishibashi M, et al.Microwave endometrial ablation as an alternative to hysterectomy for the emergent control of uterine bleeding in patients who are poor surgical candidates. Arch Gynecol Obstet. 2009; 280(2):279–282.10.1007/s00404-008-0885-z

    CrossrefGoogle Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×
  • Published online9/10/15 12:00 AM
  • __article__history--ppub9/1/15 12:00 AM